{"filing":{"accession_number":"0001193125-26-430596","cik":"0001070494","ticker":"ACAD","company_name":"ACADIA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"acad-20261023.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526430596/acad-20261023.htm"},"events":[{"id":37672,"run_id":34717,"accession_number":"0001193125-26-430596","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Elizabeth H.Z. Thompson, Ph.D., Executive Vice President and Head of Research and Development, is departing the Company effective October 23, 2026, after informing the Company of her planned retirement on April 27, 2026. While she will provide limited consulting services through December 31, 2026, the principal disclosed action is her departure from her executive officer role. The departure of a senior R\u0026D executive at a pharmaceutical company is material to investors assessing the registrant's research capabilities and leadership continuity.","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42457,"accession_number":"0001193125-26-430596","item_number":"5.02","item_title":"Departure Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Elizabeth H.Z. Thompson, Ph.D., Executive Vice President and Head of Research and Development, is departing the Company effective October 23, 2026, after informing the Company of her planned retirement on April 27, 2026. While she will provide limited consulting services through December 31, 2026, the principal disclosed action is her departure from her executive officer role. The departure of a senior R\u0026D executive at a pharmaceutical company is material to investors assessing the registrant's research capabilities and leadership continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:54:20.668911+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42457,"accession_number":"0001193125-26-430596","item_number":"5.02","item_title":"Departure Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Elizabeth H.Z. Thompson, Ph.D., Executive Vice President and Head of Research and Development, is departing the Company effective October 23, 2026, after informing the Company of her planned retirement on April 27, 2026. While she will provide limited consulting services through December 31, 2026, the principal disclosed action is her departure from her executive officer role. The departure of a senior R\u0026D executive at a pharmaceutical company is material to investors assessing the registrant's research capabilities and leadership continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:54:20.668911+00:00","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-10-23"}]}